Company Received Notice Regarding NYSE Continued Listing Standards Section 802.01B SQZ Biotechnologies (SQZ) has approved a 1-for-10 reverse stock split of its common stock, effective...
SQZ Biotechnologies Company (SQZ) delivered earnings and revenue surprises of -11.11% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
SQZ Biotechnologies press release (SQZ): Q1 GAAP EPS of -$0.60 misses by $0.06.As of March 31, 2023, the Company had cash and cash equivalents of $39.9 million and anticipates this...
Phase 1 SQZ-AAC-HPV-101 Clinical Trial Resumed Following the Observation of a Confirmed Complete Response in the First Patient in the Lowest-Dose Cohort; Anticipate Data for the Highest-Dose Cohort... | May 10, 2023
SQZ Biotechnologies (SQZ) received a notice from the New York Stock Exchange ((NYSE)) for not being in compliance with the rule of minimum $1 price of the company’s common stock...
Andrew Elnatan Brings Nearly Three Decades of Global Regulatory Experience with Successful Breakthrough Therapy Designation and Global Drug Approvals...
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of SQZ Biotechnologies Company ("SQZ" or the "Company") (NYSE: SQZ). Such...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SQZ Biotechnologies Company - SQZ
GlobeNewswire
January 02, 2023
NEW YORK, Jan. 01, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of SQZ Biotechnologies Company (“SQZ” or the “Company”) (NYSE: SQZ). Such investors are advised to...
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Feb. 10) 9 ...